IONQ vs NVDA: which stock is the better buy?
IonQ, Inc. and NVIDIA Corporation, graded by the same fixed-weight model from live fundamentals — composite score, 12-month forecast, valuation, growth and margins, side by side. As of July 6, 2026.
On today’s numbers, NVIDIA Corporation grades higher — 71/100 vs 50/100. Tap either card for the full factor breakdown.
Metric by metric
| Metric | IONQ | NVDA |
|---|---|---|
| TradersQuant Score | 50/100 | 71/100 ✓ |
| Price | $49.12 | $194.83 |
| 12-mo base forecast | $60.03 | $287.97 |
| Implied upside | +22.2% | +47.8% ✓ |
| Bull / bear range | $84.54 / $41.58 | $384.40 / $229.52 |
| P/E | 545.8 | 29.7 ✓ |
| Forward P/E | — | — |
| Revenue growth (YoY) | +201.9% ✓ | +65.5% |
| Gross margin | 38.1% | 74.1% ✓ |
| Market cap | $18.3B | $4.72T |
| Sector | Technology | Technology |
✓ marks the stronger reading per metric (lower is better for P/E). Figures refresh continuously; research, not financial advice.
Want the full verdict on IONQ and NVDA?
The AI bull/base/bear thesis, smart-money positioning, options signals and insider activity on both — every systematic call graded in public against the S&P 500.
$0 today · cancel before day 7 and you won’t be charged
IONQ vs NVDA — FAQ (2026)
Is IONQ or NVDA the better buy right now?
On the live TradersQuant composite score, NVIDIA Corporation (NVDA) currently grades higher at 71/100 versus 50/100 for IONQ. The score weighs valuation, growth, earnings quality, momentum, the macro regime, sentiment and balance-sheet risk — open each stock's page for the full breakdown. Research, not financial advice.
Which has more 12-month upside, IONQ or NVDA?
TradersQuant's 12-month base-case forecast currently implies +22.2% for IONQ and +47.8% for NVDA. Both forecasts are three-scenario models (bull/base/bear) refreshed continuously and graded on our public track record.
How is this IONQ vs NVDA comparison calculated?
Both stocks are scored by the same fixed-weight model — 20% valuation, 20% growth, 15% earnings quality, 15% momentum, 10% macro regime fit, 10% analyst sentiment, 10% balance-sheet risk — from live fundamentals and prices. No hand-picking: the same arithmetic runs on every stock we cover, and our systematic calls are graded in public against the S&P 500.